Gastroesophageal Cancer
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
Dr. Cytryn reviews the FDA approval of tislelizumab and shares thoughts on its clinical impact.
Tislelizumab is a monoclonal antibody with a high affinity and binding specificity against programmed cell death protein 1.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
Dr. Cytryn provides insights on the FDA approval of zolbetuximab and how it will impact clinical practice.
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
Advertisement
Expert Interviews on GI Oncology
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.